基于文献统计分析桑树研究的进展

通过对国内外各大数据库中桑树相关文献量的计量,对桑树的研究状况进行了分析。结果显示,桑叶作为家蚕饲料的传统农业模式已被打破,现已转向涉及医药、食品与保健等领域的多元化发展的桑树资源综合开发利用模式。其中,对桑树活性物质的研究由生物碱类物质转向多酚类物质和多糖类物质,桑树的抑制肿瘤和抗癌活性逐渐被重视,国内研究者对桑树的研究深度及影响力逐年提高。该结果可为桑树资源的进一步研究提供一定的参考。     

不同激素剂量对幼鼠超数排卵及超排卵质量的影响

应用国产激素制剂对３～８周龄昆明种小白鼠进行了超数排卵处理,重点观察了不同激素剂量对幼龄小鼠的超排效果及超排卵质量的影响。实验结果表明,以ＰＭＳＧ与ｈＣＧ各１０ＩＵ剂量超排３～８周龄小鼠,５周龄小鼠的超排效果（平均获卵８３．８±１０．２个）极显著（Ｐ＜０．０１）好于４～８周龄小鼠的超排效果（平均获卵３９．２～４９．８个）,而３周龄小鼠超排卵受精后体外培养的卵裂率（９７．１％）、桑椹胚率（８６．８％）和囊胚率（６５．１％）与４～８周龄超排卵的（分别为８５．５％～１００．０％、９４．９％～１００．０％和６３．２％～８７．７％）相近;以ＰＭＳＧ与ｈＣＧ各５ＩＵ剂量超排３～５周龄小鼠,３周龄小鼠的超排效果（平均获卵５９．０±６．５个）显著（Ｐ＜０．０５）好于４周龄小鼠的超排效果（平均获卵３１．４±４．９个）,并极显著（Ｐ＜０．０１）好于５周龄小鼠的超排效果（平均获卵２１．４±３．３个）;以ＰＭＳＧ与ｈＣＧ各１５ＩＵ剂量超排３～５周龄小鼠,３周龄小鼠的超排效果（平均获卵４８．６±７．３个）显著（Ｐ＜０．０５）好于５周龄小鼠的超排效果（平均获卵２５．２±５．８个）,也好于４周龄小鼠的超排效果（平均获卵４０．２±５．１个     

不同贮藏条件鸡蛋的脂类过氧化作用

本文以ＴＢＡ光度法分析了不同贮藏条件下鸡蛋脂类的过氧化作用,并分析了温度、氧对过氧化作用的影响。结果表明,在贮藏条件下,鸡蛋蛋黄中伴有明显的脂类过氧化过程。脂类过氧化物（ＬＰＯ）的水平随贮藏时间的延长而不断增加（Ｐ＜０．０１）,但蛋清中的ＬＰＯ在贮藏过程中没有明显的变化。低温和缺氧可明显抑制鸡蛋脂类的过氧化作用（Ｐ＜０．０１）。     

牛副结核检疫中的非特异性干扰

给犊牛接种各种分枝杆菌，然后以副结核ＰＰＤ进行变态反应试验，观察各分枝杆菌感染对副结核变态反应的干扰；从各种分枝杆菌感染牛群采取血清进行副结核ＥＬＩＳＡ检测，以观察各分枝杆菌血清对牛副结核ＥＬＩＳＡ的干扰。结果：多种分枝杆菌，特别是鸟胞内分枝杆菌、瘰疬分枝杆菌的感染可干扰副结核变态反应；部分结核牛血清干扰副结核ＥＬＩＳＡ的检测     

单效降膜式蒸发器在液态奶生产中的设计注意事项

液态奶生产中的单效降膜式蒸发器浓缩比比较小,蒸发温度不得过高,浓缩后的奶液浓度要求严格、不得有较大的波动,因此其蒸发参数要求必须稳定,无论是自动控制还是手动控制其进料质量分数、进汽压力必须稳定,这样才能获得良好的使用效果。     

貂,貉,犬病毒性肠炎快速诊断试剂的研究

用金黄葡萄球菌Ａ蛋白（ＳＰＡ）协同凝集方法（ＣｏＡ）对貂、貉、犬病毒性肠炎快速诊断的试剂进行了制备，确定了制备。艺及该制剂的标准操作程序。本制剂特异性强，不与健康动物的组织及其他几种病毒病（犬瘟热、犬传染性肝炎、狂犬病等）发生交叉凝集反应，灵敏度高，通过该制剂ＣｏＡ法与ＨＡ－ＨＩ法比较结果比现行的貂、貉、犬病毒性肠炎ＨＡ－ＨＩ诊断方法检出率高出３０％，同时具有微量、操作简便、易掌握、快速等特点，可在３～５ｍｉｎ获得诊断结果。     

三黄白术片对人工感染鸡传染性法氏囊病的疗效

３组１６日龄小鸡人工感染以鸡传染性法氏囊病（ＩＢＤ）病毒,４８ｈ后出现临床症状,分别内服三黄白术片,剂量分别为０．３７５ｇ,０．２５ｇ和０．１２５ｇ,每日２次,连服５日,随后的１０日内,治疗组分别死亡１３．３％（４／３０）、１６．７％（５／３０）和４０％（１２／３０）,而未治疗的对照组死亡５３．３％（１６／３０）。在相对增重上,治疗组分别为７３．９％、７０．１％和７１．１％,而未治疗对照组为２５．８％。     

沼液浸种对黑麦草种子发芽的影响

为了研究沼液浸种对黑麦草种子发芽的影响,设置4个浓度沼液分别浸泡黑麦草种子,分析种子各项发芽指标的变化。结果表明:各处理均能正常发芽,黑麦草种子的发芽率和发芽势等4项发芽指标均随着浸种沼液浓度的增加呈现先上升后下降的趋势,以75%沼液浓度浸种效果最优,但沼液浸种对发芽率和发芽势的影响要高于苗高和根长。综合分析认为利用沼液浸泡黑麦草种子是提高其生产性能的有力措施,适宜在生产中推广利用。     

The pharmacokinetics and metabolism of ivermectin in domestic animal species

The pharmacokinetic properties of drugs are closely related to their pharmacological efficacy. The kinetics of ivermectin are characterised, in general terms, by a slow absorption process, a broad distribution in the organism, low metabolism, and slow excretion. The kinetics vary according to the route of administration, formulation, animal species, body condition, age, and physiological status, all of which contribute to differences in drug efficacy. Characterisation of ivermectin kinetics can be used to predict and optimise the value of the parasiticide effects and to design programmes for parasite control. This article reviews the pharmacokinetics of ivermectin in several domestic animal species.     

Nitric oxide production by macrophages stimulated with Coccidia sporozoites, lipopolysaccharide, or interferon-gamma, and its dynamic changes in SC and TK strains of chickens infected with Eimeria tenella

Nitric oxide (NO) is an important mediator of innate and acquired immunities. In the studies reported here, we quantified NO produced in vitro by chicken leukocytes and macrophages and in vivo during the course of experimental infection with Eimeria, the causative agent of avian coccidiosis, and identified macrophages as the primary source of inducible NO. Eimeria tenella-infected chickens produced higher levels of NO compared with noninfected controls. In Eimeria-infected animals, SC chickens produced greater amounts of NO compared with infected TK chickens, particularly in the intestinal cecum, the region of the intestine infected by E. tenella. Macrophages that were isolated from normal spleen were a major source of NO induced by interferon (IFN)-gamma, lipopolysaccharide (LPS), and E. tenella sporozoites. Macrophage cell line MQ-NCSU produced high levels of NO in response to Escherichia coli or Salmonella typhi LPS, whereas the HD-11 macrophage cell line was more responsive to IFN-gamma. These findings are discussed in the context of the genetic differences in SC and TK chickens that may contribute to their divergent disease phenotypes.